There was no significant difference in the composite end point at 7 days [ 0.8 % ( 1/122 ) vs. 3.2 % ( 4/124 ) , P = 0.38 ] between the groups , however , there was a trend towards lower composite efficacy end points at 6 months in tirofiban group compared to control group [ 0.9 % ( 1/117 ) vs. 5.9 % ( 7/118 ) , P = 0.07 ] .